We are live on ! Find out more
ADVM

Adverum Biotechnologies
ADVM

Delisted

ADVM was delisted on the 8th of December, 2025.

Back to rankings

0 hedge funds and large institutions have $0 invested in Adverum Biotechnologies in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

67.07% less ownership

Funds ownership: 67.07% → 0% (-67%)

100% less funds holding

Funds holding: 50 → 0 (-50)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less capital invested

Capital invested by funds: $63.8M → $0 (-$63.8M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 50

Holders
–
Holders Change
-50
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
50
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
-$13.9M
2
PWA
Principia Wealth Advisory
Texas
-$9.41M
3
FLSM
Frazier Life Sciences Management
California
-$9.41M
4
TCM
TCG Crossover Management
California
-$7.56M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$3.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
1
BML Capital Management
Indiana
– -$13.9M -3,057,526 Closed
PWA
2
Principia Wealth Advisory
Texas
– -$9.41M -2,077,946 Closed
FLSM
3
Frazier Life Sciences Management
California
– -$9.41M -2,077,431 Closed
TCM
4
TCG Crossover Management
California
– -$7.56M -1,668,174 Closed
Vanguard Group
5
Vanguard Group
Pennsylvania
– -$3.95M -872,041 Closed
5VM
6
5AM Venture Management
California
– -$2.45M -541,666 Closed
VVM
7
Versant Venture Management
California
– -$2.3M -506,821 Closed
Goldman Sachs
8
Goldman Sachs
New York
– -$1.82M -402,581 Closed
Renaissance Technologies
9
Renaissance Technologies
New York
– -$1.65M -363,496 Closed
PFCS
10
Pale Fire Capital SE
Czech Republic
– -$1.65M -363,282 Closed
Millennium Management
11
Millennium Management
New York
– -$1.47M -324,422 Closed
BlackRock
12
BlackRock
New York
– -$1.41M -311,394 Closed
SCM
13
Soleus Capital Management
Connecticut
– -$1.3M -287,246 Closed
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
– -$1.06M -234,541 Closed
Geode Capital Management
15
Geode Capital Management
Massachusetts
– -$837K -184,762 Closed
RP
16
Regeneron Pharmaceuticals
New York
– -$820K -180,909 Closed
WA
17
Waverly Advisors
Alabama
– -$729K -160,991 Closed
Two Sigma Investments
18
Two Sigma Investments
New York
– -$402K -88,670 Closed
State Street
19
State Street
Massachusetts
– -$311K -68,734 Closed
QOP
20
Quinn Opportunity Partners
Virginia
– -$188K -41,418 Closed
Two Sigma Advisers
21
Two Sigma Advisers
New York
– -$172K -38,071 Closed
Marshall Wace
22
Marshall Wace
United Kingdom
– -$129K -28,367 Closed
Northern Trust
23
Northern Trust
Illinois
– -$127K -28,058 Closed
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
– -$119K -26,255 Closed
Qube Research & Technologies (QRT)
25
Qube Research & Technologies (QRT)
United Kingdom
– -$98.4K -21,730 Closed
1
2

ADVM Hedge Fund Activity: Q4 2025 in Review

0 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2025, worth a combined $0 — down 100% from $63.8M a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of ADVM and 0 opened new positions — a net loss of 50 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BML Capital Management, exiting entirely with an estimated $13.9M sold.

  • 0 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2025, down from 50 in Q3 2025.
  • Funds reported $0 of Adverum Biotechnologies stock for Q4 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Adverum Biotechnologies positions in Q4 2025 and 50 closed out, a net change of -50 holders.
  • The largest Adverum Biotechnologies seller in Q4 2025 was BML Capital Management, an estimated $13.9M sold.

Based on aggregated 13F filings for Q4 2025.